LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Greiner Bio-One to Serve Spain and Portugal through Distribution Subsidiaries

By LabMedica International staff writers
Posted on 28 Mar 2017
Print article
Greiner Bio-One has acquired its long-standing distribution partners, VacuetteEspaña and Vacuette Portugal, which will now allow the medical technology company to serve its customers in Spain and Portugal directly through its own distribution subsidiaries.

Greiner Bio-One, a part of the Greiner Group, specializes in the development, production and distribution of high-quality plastic products for laboratory use. The company is a technology partner for hospitals, laboratories, universities, research institutes, the diagnostic and pharmaceutical industry and biotechnology.

For over 20 years, the Greiner Group has worked with VacuetteEspaña, S.A. and Vacuette Portugal Importação e Exportação de Material Hospitalar, S.A., both of which were previously exclusive distributors for Greiner Bio-One International on the Iberian Peninsula. Towards the end of February 2017, Greiner Bio-One entered into official acquisition agreements with both of its distribution partners that came into effect on March 1, 2017. The two subsidiaries in Madrid and Porto will now continue to supply directly to their customers in both the markets.

“Having our own local subsidiaries will bring us closer to our customers and enable us to cater to our markets even more effectively at an international level. The acquisition of VacuetteEspaña and Vacuette Portugal is another key step in our globalization strategy,” said Axel Kühner, Chairman of the Management Board of the Greiner Group.

“Following the establishment of our own distribution subsidiaries in Turkey and Italy last year, the new Greiner Bio-One sites in Spain and Portugal are the next step in systematic implementation of our distribution strategy in Europe,” added Rainer Perneker, CEO of Greiner Bio-One International.

“By attaining greater proximity to customers, we aim to develop the two markets on the Iberian Peninsula in an even more targeted way. The acquisitions mark the continuation of our growth over many years and allow us to step up services and customer care at the local level,” said Manfred Buchberger, CEO of Greiner Bio-One Preanalytics.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more